Nocturne Acquisition Corp is a United States-based company. The Company is a shell company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The Company has no operations and has not generated revenues.

Employees

Sector

Investment Holding Companies

More about the company

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-03 pm EDT			5-day change	1st Jan Change
11.66 ^USD	-0.49%		-.--%	-

24-04-02	Nocturne Acquisition Corporation(NasdaqCM:MBTC) dropped from NASDAQ Composite Index	CI
24-03-30	Cognos Therapeutics Inc. cancelled the acquisition of Nocturne Acquisition Corporation from a group of shareholders in a reverse merger transaction.	CI

Capitalization	60.48M 51.46M 47.2M 44.77M 82.55M 5.66B 84.39M 554M 218M 2.71B 227M 222M 9.64B	P/E ratio 2021	-163x	P/E ratio 2022	-78.5x
Enterprise value	64.05M 54.5M 49.98M 47.42M 87.43M 5.99B 89.37M 587M 231M 2.88B 240M 235M 10.21B	EV / Sales 2021	-	EV / Sales 2022	-
Free-Float	23.5%	Yield 2021 *	-	Yield 2022	-

24-04-02	Nocturne Acquisition Corporation(NasdaqCM:MBTC) dropped from NASDAQ Composite Index	CI
24-03-30	Cognos Therapeutics Inc. cancelled the acquisition of Nocturne Acquisition Corporation from a group of shareholders in a reverse merger transaction.	CI
24-02-07	Nocturne Acquisition Corporation Announces Management Changes	CI
24-02-05	Nocturne Acquisition Shares Jump as Stockholders' Vote on Merger With Cognos Therapeutics Postponed Further	MT
23-11-22	Nocturne Acquisition Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-08-21	Nocturne Acquisition Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-06-23	Nocturne Acquisition Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-05-26	Nocturne Acquisition Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-05-25	Nocturne Acquisition Corporation Auditor Raises 'Going Concern' Doubt	CI
23-01-03	Nocturne Acquisition in Deal to Merge With Cognos Therapeutics	MT
23-01-02	Cognos Therapeutics Inc. executed a definitive business combination agreement to acquire Nocturne Acquisition Corporation from Nocturne Sponsor, LLC, Polar Asset Management Partners Inc., Periscope Capital Inc, Sea Otter Advisors LLC and others for approximately $120 million in a reverse merger transaction.	CI
22-11-21	Nocturne Acquisition Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-08-22	Nocturne Acquisition Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI

23-09-20	Chardan Engaged to Facilitate Nocturne Acquisition Corporation's Business Combination with Cognos Therapeutics, Inc., Paving the Way for NASDAQ Listing	AQ
23-05-02	NOCTURNE ACQUISITION CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
23-04-14	NOCTURNE ACQUISITION CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
23-04-06	NOCTURNE ACQUISITION CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
23-04-03	NOCTURNE ACQUISITION CORP : Regulation FD Disclosure (form 8-K)	AQ

Cognos Therapeutics Holdings, Inc. Stock

Equities

MBTC

KYG6580S1140

Investment Holding Companies

Valuation: Cognos Therapeutics Holdings, Inc.

Latest news: Cognos Therapeutics Holdings, Inc.

Press Releases: Cognos Therapeutics Holdings, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Cognos Therapeutics Holdings, Inc.

Shell Companies

Financials

Company Profile

Manager	Title	Age	Since
Henry Monzon CEO	Chief Executive Officer	52	2020-10-27
Ka Seng Ao DFI	Director of Finance/CFO	37	2020-10-27
Haoyu Lin PRN	Corporate Officer/Principal	37	2024-02-01

Director	Title	Age	Since
Henry Monzon CHM	Chairman	52	2020-10-27
Ka Seng Ao BRD	Director/Board Member	37	2020-10-27
Hon Keung Choi BRD	Director/Board Member	65	2021-12-15

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
COGNOS THERAPEUTICS HOLDINGS, INC.	-0.49%	-.--%	-.--%	+5.90%	56.65M
PRIME BEING CORP.	-14.57%	-14.57%	+209.03%	+658.93%	1.23B
CHURCHILL CAPITAL CORP VII	-0.30%	-.--%	-.--%	-1.67%	915M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	0.00%	0.00%	-	-	656M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	-.--%	-.--%	-.--%	600M
BAIN CAPITAL GSS INVESTMENT CORP.	0.00%	+0.59%	-	-	595M
CANTOR EQUITY PARTNERS IV, INC.	+0.10%	+0.49%	-	-	586M
CHURCHILL CAPITAL CORP XI	+1.03%	+0.98%	-	-	567M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-1.60%	-0.54%	-	-	555M
NEW AMERICA ACQUISITION I CORP.	+0.20%	+0.70%	-	-	501M
Average	-1.56%	+0.26%	+52.26%	+165.79%	626.34M
Weighted average by Cap.	-2.94%	+0.20%	+91.84%	+289.08%

	2021	2022
Net sales	-	-
Net income	-710K -604K -554K -526K -969K -66.43M -991K -6.51M -2.56M -31.88M -2.66M -2.61M -113M	-1.21M -1.03M -943K -895K -1.65M -113M -1.69M -11.07M -4.36M -54.24M -4.53M -4.44M -193M
Net Debt	-385K -327K -300K -285K -525K -35.97M -536K -3.52M -1.39M -17.26M -1.44M -1.41M -61.3M	3.57M 3.04M 2.79M 2.64M 4.88M 334M 4.98M 32.74M 12.88M 160M 13.4M 13.12M 570M

3 years	9.45	13.98
5 years	9.45	13.98
10 years	9.45	13.98